Join us on 12-15-2022 for a live seminar about RNA SEQ

Click Here

Media

CASE STUDIES

PERSPECTIVES

NEWS

Case Studies

Learn how we partner with the global drug discovery community to help them advance the best drug candidates.

Perspectives

Hear from Alloy Therapeutics leadership on our latest advances into new modalities and the why behind our work.

Announcements

""/

Alloy Therapeutics Announces Scientific Advisory Board to Drive Roadmap of Biotherapeutic Discovery Platform Innovation

Alloy Therapeutics Announces Scientific Advisory Board to Drive Roadmap of Biotherapeutic Discovery Platform Innovation.

BOSTON, Mass. – September 20, 2023 — Alloy Therapeutics, a biotechnology ecosystem company, announced the formation of its scientific advisory board (SAB) that includes a group of renowned experts in fields spanning immunology, protein engineering, T cell receptor (TCR) modalities, and more. Alloy’s SAB members have been instrumental in developing Alloy’s technical roadmap as the company has developed cutting edge technologies and services across antibodies, bispecifics, TCRs and TCR mimics, genetic medicines, cell therapies, peptides and drug delivery technologies.

“Alloy’s mission is to support our drug discovery partners by developing and providing broad access to innovative technologies and platforms. Innovation and focus on quality drive our highly collaborative and science-focused R&D team,” explained Alloy President and Head of Research Piotr Bobrowicz, PhD. “We are thankful to our SAB members for their partnership in guiding us in this process. Their valuable feedback continuously shapes our technical roadmap.”

The SAB’s collaboration with Alloy will inform new areas of platform development and innovation, as well as identify promising areas of disease biology that can benefit from Alloy’s established portfolio of platforms, services, and company creation capabilities. This esteemed group includes:

  • Matthew DeLisa, PhD, William L. Lewis Professor of Engineering and Director of the Institute of Biotechnology at Cornell University, whose expertise spans synthetic glycobiology, immunoengineering, protein engineering and vaccine development.
  • Sai Reddy, PhD, Associate Professor of Systems and Synthetic Immunology at ETH Zurich, and an expert in the use of high-throughput antibody repertoire sequencing and computational biology to understand the immune response. Dr. Reddy previously co-founded deepCDR Biologics, a deep learning antibody discovery platform acquired by Alloy in December 2021.
  • Darrell Irvine, PhD, Professor at the MIT Koch Institute for Integrative Cancer Research, Howard Hughes Medical Institute Investigator, and a leading researcher in the use of materials science and engineering tools to develop novel technologies for drug delivery, vaccine development, and cancer immunotherapies.
  • Christopher Love, PhD, Professor in Chemical Engineering at the MIT Koch Institute for Integrative Cancer Research, and an expert in single-cell sequencing, systems immunology, next-generation protein biopharmaceuticals, and alternative host strain engineering.
  • Jeff Molldrem, MD, Professor and Chair of the Department of Hematopoietic Biology and Malignancy at the University of Texas MD Anderson Cancer Center whose expertise spans TCRs, TCR mimics, and tumor immunology.
  • Randolph Noelle, PhD, Emeritus Professor of Microbiology and Immunology at Dartmouth University, and a leading researcher in the areas of regulatory T cell biology, B cell memory and plasma cell development, immune tolerance, cancer vaccines, and translational immunotherapy.
  • Kai Toellner, PhD, Professor of Adaptive Immunology at the University of Birmingham, and an expert in B cell differentiation, germinal centers, and the regulation of affinity maturation and immunoglobulin class switching.
  • Andrew Sewell, PhD, Professor at the Systems Immunity Research Institute at Cardiff University, and a world-leading expert in T cell biology research focused on understanding how T cells recognize their targets and applying these insights to create novel immunotherapies.

Alloy’s scientific teams collaborate closely with SAB members across the technology roadmap. Jeff Molldrem, MD remarked, “Alloy’s leading technology for development of TCRs and TCR mimic antibodies, combined with the unique business model that affords clients and partners broad access to that technology, has made our collaboration with the Alloy team stand out as truly unique and rapidly productive.” Kai Toellner, PhD added, “The collaboration with Alloy led to the development of several mouse models that enabled us to study mechanisms of B cell differentiation, leading to the appearance of high affinity antibodies.”

Alloy continues to invest 100% of its revenue back into innovation as well as access to innovation and will leverage insights from SAB members to make thoughtful decisions regarding the next generation of biologics drug discovery platform innovations. Randolph Noelle, PhD commented: “The biotech/pharmaceutical industries are continuously evolving, and the integration of state-of-the-art technologies will drastically improve their ability to more efficiently produce safe and effective drugs. The breadth, depth and creativeness of the technologies that Alloy offers, together with the overwhelming expertise to implement these technologies provides unprecedented opportunities for the marketplace to produce better medicines. Never before has such a portfolio of opportunity been available.”

In addition to its SAB, Alloy announced earlier this year the formation of an independent, genetic medicines-focused scientific advisory board to support the development of its proprietary AntiClastic™ Antisense Oligonucleotide (AntiClastic ASO) platform.

About Alloy Therapeutics

Alloy Therapeutics is a biotechnology ecosystem company empowering the global scientific community to make better medicines together. Through a community of partners across academia, biotech, and the largest biopharma, Alloy democratizes access to pre-competitive tools, technologies, services, and company creation capabilities that are foundational for discovering and developing therapeutic biologics across six modalities: antibodies, TCRs, genetic medicines, peptides, cell therapies, and drug delivery. Partners may access all current and future technologies through a discovery service relationship or for a flat annual fee through Alloy’s Innovation Subscriptions offering. As a reflection of Alloy’s relentless commitment to the scientific community, Alloy reinvests 100% of its revenue in innovation and access to innovation.

Join the Alloy Therapeutics community by visiting alloytx.com, following Alloy on LinkedIn, scheduling a 15-minute introductory call with our team at alloytx.com/bd, or a 15-minute chat with Alloy’s Founder and CEO at alloytx.com/ceo.

###

Contact

Russell Beckerman

[email protected]


Read more press coverage of the collaboration:

High Efficiency CAR Discovery & Screening

Chimeric antigen receptor cell therapy (CAR-T, CAR-NK, etc.) is a promising therapeutic modality, but functional screening is a bottleneck for traditional two-step CAR-T discovery process of antibody binder discovery and CAR-T functional engineering. In this webinar, scientists at Alloy showcase their unique CAR discovery workflow that incorporates human antibody identification and characterization, mRNA-based CAR construct generation, and in vitro and in vivo functional screening. Learn from the discovery scientists that helm this process and help cell therapy companies and discovery teams identify functional chimeric antigen receptors three months faster than conventional approaches.

 

High Efficiency CAR Discovery & Screening

""/

Alloy Therapeutics Expands Executive Team to Strengthen Therapeutic Discovery and Innovation for Its Partners

Biotherapeutic discovery and development expert Michael Schmidt joins as CSO to manage an expansive roadmap of technical innovation across Alloy’s platforms, services, and company formation in six modalities.

Alloy’s Martin Leach is promoted to COO to expand the company’s operational excellence and discovery services capacity for partners.

BOSTON, Mass. – June 28, 2023 — Alloy Therapeutics, a biotechnology ecosystem company, announced expanded leadership to strengthen its portfolio of drug discovery capabilities and technologies for the global scientific community. Michael Schmidt, PhD has joined the company as its Chief Scientific Officer (CSO), where he will oversee technical innovation and ensure high scientific quality for Alloy’s broad portfolio of platforms, services, and venture studio company creation. Alloy has promoted Martin Leach, PhD, MBA to Chief Operating Officer (COO), from his previous position of Alloy Senior Vice President of Global Informatics and COO of its Daedamab research facility.

Dr. Schmidt was most recently CSO at Ankyra Therapeutics, where he oversaw optimization of a novel intratumoral drug retention platform and development of Ankyra’s differentiated IL-12 cytokine therapy. Previously, he worked at Eleven Biotherapeutics (now Carisma Therapeutics, NASDAQ: CARM) and Compass Therapeutics (NASDAQ: CMPX) leading discovery and development of monoclonal and bispecific antibody drugs in the areas of immuno-oncology and ocular diseases. He received his PhD from MIT, where he focused on the engineering of antibodies for improved targeting of solid tumors.

“I have seen firsthand how time-consuming and expensive it is to build the technology platforms and teams needed to discover and advance a great clinical candidate, and I am drawn to Alloy’s model of centralizing this expertise to help the best assets advance more quickly,” said Schmidt. “I am proud to support this talented team in their impressive pace of new technology development, while engaging with the venture studio around efficiently advancing new medicines discovered from Alloy’s core platform technologies.”

Piotr Bobrowicz, PhD, formerly Alloy’s CSO and President, will now collaborate with Schmidt in his role as President to oversee Alloy’s expansive roadmap for new technology innovations and engage with Alloy’s Scientific Advisory Board (SAB) for ongoing innovation. They will also lead the scientific diligence process for the new companies that ultimately advance through 82VS, Alloy’s affiliated venture studio, which efficiently launches multi-asset startups leveraging the expertise and technology from the Alloy ecosystem at large.

Dr. Leach has been instrumental in strengthening Alloy’s Antibody Discovery Services business, through launching its Athens, GA site—which pioneered Alloy’s sequence-first antibody discovery workflow SeqImmune—and expanding Alloy’s global informatics function to support all partner campaigns. He previously held leadership roles in R&D operations and technology for organizations such as Alexion Pharmaceuticals (as VP R&D, Global Operations and Global Quality IT), Biogen (as VP, Head of Global Data Office), The Broad Institute (as Chief Information Officer), Merck, and CuraGen. He received his MBA from the MIT Sloan School of Management and his PhD from Boston University School of Medicine in molecular pharmacology.

“I am eager to apply my expertise in scaling discovery operations and high-performing technical teams to the breadth of Alloy’s capabilities across six modalities and five research sites—all in service of accelerating the quality and speed with which we support drug developers,” said Leach.

“We are thrilled to have Mike’s world-class expertise in antibody discovery and engineering and deep biotech startup experience collaborating with Piotr in steering the Alloy scientific team and roadmap,” said Alloy CEO and Founder, Errik Anderson, who previously worked with Dr. Schmidt during his time as COO and co-founder of Compass Therapeutics. “Additionally, Martin’s experience in rapidly scaling our informatics function and our Daedamab operation is an incredible asset as we grow our capacity in helping our ecosystem partners discover new therapeutics more efficiently.”

About Alloy Therapeutics

Alloy Therapeutics is a biotechnology ecosystem company empowering the global scientific community to make better medicines together. Through a community of partners across academia, biotech, and the largest biopharma, Alloy democratizes access to pre-competitive tools, technologies, services, and company creation capabilities that are foundational for discovering and developing therapeutic biologics across six modalities: antibodies, TCRs, genetic medicines, peptides, cell therapies, and drug delivery. Partners may access all current and future technologies through a discovery service relationship or for a flat annual fee through Alloy’s Innovation Subscriptions offering. As a reflection of Alloy’s relentless commitment to the scientific community, Alloy reinvests 100% of its revenue in innovation and access to innovation.

Join the Alloy Therapeutics community by visiting alloytx.com, following Alloy on LinkedIn, scheduling a 15-minute introductory call with our team at alloytx.com/bd, or a 15-minute chat with Alloy’s Founder and CEO at alloytx.com/ceo.

###

Contact

Erin Glabets

[email protected]


Read more press coverage of the collaboration:

Ecosystem News & Coverage

High Efficiency CAR Discovery & Screening

Alloy Webinar Recording

Scientific Advisory Board Roadmap

Announcement

High Efficiency CAR Discovery & Screening

Alloy Webinar Recording

AntiClastic ASO Platform Launch

Announcement

Lundbeck Discovery Collaboration

Announcement

Alloy 2023 Year of Innovation

Announcement

82VS President Trier Bryant

Hiring Announcement

Q&A with Alloy CEO Errik Anderson

PharmaExec

Aakha Biologics

New Headquarters

Sudhir Agrawal Partnership

Announcement

Wheeler Bio

Seed Funding Announcement

Making Better Medicines

Nature Special Issue

Approaches to Binder Recovery

Alloy White Paper

Alloy & Pyxis Form Voxall

Launch Announcement

Antibody Discovery Expansion

Announcement

Woman of the Week Trier Bryant

PharmaVoice Podcast

Alloy Series D

Financing Announcement

Biotech Incubators Review

Biopharm International

Woman of the Week Heather Schwoebel

PharmaVoice Podcast

Targeting GPCRs with DeepImmune

Alloy White Paper

Mytide Therapeutics

Funding Announcement

Vernal Biosciences

Funding Announcement

Alloy Acquires deepCDR Biologics

Announcement

Alloy & Echo Create Wheeler Bio

Launch Announcement

Alloy & Maze Form Broadwing Bio

Launch Announcement

Lambda Light Chain Antibody Discovery

Alloy White Paper

Normunity Discovery Collaboration

Announcement

Democratizing Biologics Discovery

GenEdge Story

Wheeler Bio

Series A Announcement

Discovery Against Challenging Targets

Alloy Webinar Recording

23 Biotech Startups Set to Take off

Business Insider List

MIT Marble Center

IAMNano Launch Announcement

Building a Biotech Ecosystem

BIOS Builders Interview

Aakha Biologics

BioLabs Incubator Launch

Democratizing Drug Discovery

The BioReport Podcast

Approaches to Binder Recovery

Alloy Webinar Recording

Vernal Biosciences

Launch Announcement

Media Inquiries


Alloy Therapeutics is a biotechnology ecosystem company empowering the global scientific community to make better medicines together. Through a community of partners across academia, biotech, and the largest biopharma, Alloy democratizes access to tools, technologies, services, and company creation capabilities that are foundational for discovering and developing therapeutic biologics. 

Accept Privacy Settings Here
We use cookies to enhance your experience while using our website. If you are using our Services via a browser you can restrict, block or remove cookies through your web browser settings. We also use content and scripts from third parties that may use tracking technologies. You can selectively provide your consent below to allow such third party embeds. For complete information about the cookies we use, data we collect and how we process them, please read and Privacy Policy
Youtube
Consent to display content from Youtube
Vimeo
Consent to display content from Vimeo
Google Maps
Consent to display content from Google
Spotify
Consent to display content from Spotify
Sound Cloud
Consent to display content from Sound